Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer
Journal of Clinical Oncology, Volume 24, No. 18, Year 2006
Notification
URL copied to clipboard!
Description
Purpose: This open-label, randomized, multicenter, phase III study compared oral topotecan versus intravenous (IV) docetaxel in patients with previously treated non-small-cell lung cancer (NSCLC). Patients and Methods: Patients with stage III or IV NSCLC, performance status ≤ 2, who had received only one prior chemotherapy regimen, were randomly assigned to treatment with oral topotecan 2.3 mg/m2/d on days 1 to 5 or IV docetaxel 75 mg/m 2 day 1 every 21 days. Results: A total of 829 patients were randomly assigned. In intent-to-treat analysis, 1-year survival rates were 25.1% with topotecan and 28.7% with docetaxel. The difference of -3.6% (95% CI, -9.59% to 2.48%) met the predefined criteria for noninferiority of topotecan relative to docetaxel because the lower limit of the 95% CI was above -10%. Median survival was 27.9 weeks with topotecan and 30.7 weeks with docetaxel. Although not statistically significant (log-rank P = .057), the higher survival rate with docetaxel was maintained across the entire treatment period. The median time to progression was 11.3 weeks with topotecan versus 13.1 weeks with docetaxel (log-rank P = .02). The overall response rate was 5% in each group. Grade 3/4 neutropenia occurred more frequently with docetaxel (60% v 50%). Grade 3/4 anemia and thrombocytopenia occurred more frequently with topotecan (26% v 10% and 26% v 7%, respectively). Conclusion: Oral topotecan provides activity in the treatment of relapsed, locally advanced, unresectable NSCLC. Both regimens were well tolerated with differing safety profiles. Topotecan may provide an option for patients who desire an orally available treatment after relapse. © 2006 by American Society of Clinical Oncology.
Authors & Co-Authors
Ramlau, Rodryg Adam
Canada, Toronto
Princess Margaret Cancer Centre
Krzakowski, M. J.
Canada, Toronto
Princess Margaret Cancer Centre
von Pawel, Joachim V.
Canada, Toronto
Princess Margaret Cancer Centre
Kaukel, Eckhardt
Canada, Toronto
Princess Margaret Cancer Centre
Abratt, Raymond Pierre
Canada, Toronto
Princess Margaret Cancer Centre
Grotzinger, Kelly M.
Canada, Toronto
Princess Margaret Cancer Centre
Shepherd, Frances Alice
Canada, Toronto
Princess Margaret Cancer Centre
Statistics
Citations: 104
Authors: 7
Affiliations: 1
Identifiers
Doi:
10.1200/JCO.2005.03.6491
ISSN:
0732183X
Research Areas
Cancer
Health System And Policy